WHITE PAPER - Stop Guessing. Start Predicting: Rethinking Early Oral Drug Development
Why Early Development Requires a Different Decision Model
Early oral drug development is an exercise in working under constraint. Teams are asked to make consequential decisions when materials are limited, timelines are tight, and the data are incomplete. Traditionally, formulation development has relied on empirical, sequential experimentation. While this approach remains essential, it can be costly in early development. When issues with solubility, permeability, or bioavailability arise,
repeated reiterations can quickly consume limited API and valuable time.
This shift is fueled by a rapidly growing industry interest in digital tools. Beyond simply saving time, there is a rising recognition that digital tools, specifically ones that use AI and ML, provide a level of predictive certainty that physical trials simply cannot match in terms of time and costs at this stage. Modern drug developers are increasingly looking to AI-driven models not as a replacement for the lab, but as a strategic necessity to justify early-stage
capital investment and navigate complex regulatory pathways with data-driven confidence.
A different decision model is gaining traction in early development. Predictive formulation insights allow teams to
narrow their empirical work on what is most likely to succeed, improving development efficiency without replacing experimental science. Using AI in early drug development help narrow experimental paths and reduce unproductive trails to preserve scarce API, accelerate learning, and generate data that support confident discussions with regulators and investors. Importantly, this early development phase forms the foundation of how customers demonstrate asset visibility through clear scientific rationale, more reliable timelines, and more efficient use of
limited materials.
Total Page Views: 53
